Workflow
Intellia Therapeutics Announces Second Quarter 2025 Financial Results and Highlights Recent Company Progress

Core Insights - Intellia Therapeutics reported strong operational progress and financial results for Q2 2025, highlighting advancements in its CRISPR-based therapies for hereditary angioedema (HAE) and transthyretin (ATTR) amyloidosis [1][2]. Operational Highlights - Enrollment in the Phase 3 MAGNITUDE trial for nexiguran ziclumeran (nex-z) in ATTR-CM is ahead of projections, with plans to expand total enrollment to approximately 1,200 patients [4][9]. - The company expects to complete enrollment in the MAGNITUDE-2 study for hereditary ATTR amyloidosis with polyneuropathy (ATTRv-PN) by the first half of 2026 [4]. - Randomization in the Phase 3 HAELO study for lonvoguran ziclumeran (lonvo-z) is anticipated to be completed in Q3 2025 [4][5]. - Intellia ended Q2 2025 with approximately $630.5 million in cash and equivalents, expected to fund operations into the first half of 2027 [4][10]. Financial Results - Collaboration revenue for Q2 2025 was $14.2 million, up from $6.9 million in Q2 2024, primarily due to cost reimbursements from Regeneron Pharmaceuticals [10]. - Research and development expenses decreased to $97.0 million in Q2 2025 from $114.2 million in Q2 2024, driven by lower employee-related costs and stock-based compensation [10]. - General and administrative expenses also decreased to $27.2 million in Q2 2025 from $31.8 million in Q2 2024 [10]. - The net loss for Q2 2025 was $101.3 million, an improvement from a net loss of $147.0 million in Q2 2024 [10][18]. Upcoming Events - Intellia will participate in several conferences in Q3 2025, including the Citi 2025 Biopharma Back to School Conference and the Wells Fargo Health Care Conference [10].